- Home
- MPAA vs TNXP Comparison
MPAA vs TNXP Comparison
Compare MPAA & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPAA
- TNXP
- Stock Information
- Founded
- MPAA 1968
- TNXP 2007
- Country
- MPAA United States
- TNXP United States
- Employees
- MPAA N/A
- TNXP N/A
- Industry
- MPAA Auto Parts:O.E.M.
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- MPAA Consumer Discretionary
- TNXP Health Care
- Exchange
- MPAA Nasdaq
- TNXP Nasdaq
- Market Cap
- MPAA 188.9M
- TNXP 207.5M
- IPO Year
- MPAA 1994
- TNXP N/A
- Fundamental
- Price
- MPAA $9.76
- TNXP $33.33
- Analyst Decision
- MPAA
- TNXP Strong Buy
- Analyst Count
- MPAA 0
- TNXP 2
- Target Price
- MPAA N/A
- TNXP $585.00
- AVG Volume (30 Days)
- MPAA 199.8K
- TNXP 1.1M
- Earning Date
- MPAA 06-09-2025
- TNXP 08-15-2025
- Dividend Yield
- MPAA N/A
- TNXP N/A
- EPS Growth
- MPAA N/A
- TNXP N/A
- EPS
- MPAA N/A
- TNXP N/A
- Revenue
- MPAA $757,354,000.00
- TNXP $10,041,000.00
- Revenue This Year
- MPAA $7.74
- TNXP $11.66
- Revenue Next Year
- MPAA N/A
- TNXP $793.18
- P/E Ratio
- MPAA N/A
- TNXP N/A
- Revenue Growth
- MPAA 5.53
- TNXP N/A
- 52 Week Low
- MPAA $5.16
- TNXP $6.76
- 52 Week High
- MPAA $12.72
- TNXP $137.25
- Technical
- Relative Strength Index (RSI)
- MPAA 40.16
- TNXP 52.50
- Support Level
- MPAA $10.28
- TNXP $33.41
- Resistance Level
- MPAA $10.97
- TNXP $37.42
- Average True Range (ATR)
- MPAA 0.75
- TNXP 3.48
- MACD
- MPAA -0.22
- TNXP -1.12
- Stochastic Oscillator
- MPAA 6.33
- TNXP 33.66
About MPAA Motorcar Parts of America Inc.
Motorcar Parts of America Inc is a supplier of automotive aftermarket non-discretionary replacement parts and test solutions and diagnostic equipment. It operate in the non-discretionary automotive aftermarket for replacement hard part in North America and includes products such as light-duty rotating electrical products, wheel hub products, brake-related products, and turbochargers. In addition, it sell test solutions and diagnostic equipment. The company operates in three segments Hard Parts, Test Solutions and Diagnostic Equipment, and Heavy Duty. Key revenue is generated from Hard Parts, which includes (i) light duty rotating electric products such as alternators and starters, (ii) wheel hub products, (iii) brake-related products, including brake calipers, brake boosters, brake rotors.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.